News Formal

$11 billion drugmaker Mylan and US drug giant Pfizer are teaming up to reshape Mylan’s business. 3 tough questions from Wall Street analyst show the challenging road ahead.

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 51%

Sverige Nyheter Nyheter

Sverige Senaste nytt,Sverige Rubriker

Wall Street analysts asked big questions about the new company's future. Execs occasionally got testy.

Three tough questions from Wall Street analysts on a Monday conference call show why the spinoff could face an uphill battle.

A major deal announced on Monday will combine generic drugmaker Mylan with a unit of Pfizer that makes off-patent products like Viagra., best known for making the EpiPen allergy shot. Mylan's shares have lost almost half their value over the past year, though they surged 14% on Monday after the deal was announced. Pfizer's stock fell 2%.

Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer:

 /  🏆 729. in SE
 

Tack för din kommentar. Din kommentar kommer att publiceras efter att ha granskats.

Sverige Senaste nytt, Sverige Rubriker

Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.

Fewer investors have a 'fear of missing out,' so it may be time to buckle up, market bull suggestsOppenheimer Asset Management's John Stoltzfus expects wave of volatility to pressure stocks due to uncertainty. FuturesNow ohh it's going to be a a good dump for sure!
Källa: CNBC - 🏆 12. / 72 Läs mer »